FDA Approves New Drug Application for the DoD’s Advanced Anticonvulsant System Program
FORT DETRICK, Md. – August 23, 2022 – The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND’s) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) received notice of U.S. Food and Drug Administration (FDA) approval of Rafa Laboratories, Ltd.’s (Rafa) midazolam injection autoinjector New Drug Application…